Zai Lab And argenx Get Approval For Efgartigimod Alfa SC Injection For Generalized Myasthenia Gravis In China
Portfolio Pulse from Benzinga Newsdesk
Zai Lab and argenx have received approval from the NMPA for their subcutaneous injection, efgartigimod alfa SC, for the treatment of generalized myasthenia gravis (gMG) in China. This is the first and only NMPA-approved SC injectable for gMG, offering additional flexibility and optionality for patients. The approval is based on the consistent clinical benefit and safety profile demonstrated in the Phase 3 ADAPT-SC study.
July 16, 2024 | 5:13 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
argenx has received NMPA approval for its subcutaneous injection, efgartigimod alfa SC, for the treatment of generalized myasthenia gravis in China. This approval could enhance argenx's market presence and revenue potential in China.
The approval of efgartigimod alfa SC in China opens a new market for argenx, potentially increasing its revenue and market presence. The consistent clinical benefit and safety profile demonstrated in the Phase 3 study further support its potential success.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Zai Lab has received NMPA approval for its subcutaneous injection, efgartigimod alfa SC, for the treatment of generalized myasthenia gravis in China. This approval could enhance Zai Lab's market presence and revenue potential in China.
The approval of efgartigimod alfa SC in China opens a new market for Zai Lab, potentially increasing its revenue and market presence. The consistent clinical benefit and safety profile demonstrated in the Phase 3 study further support its potential success.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100